Although visual acuity is the most frequently used primary outcome measure in clinical trials of treatments for choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback